KRAS Inhibitors Market Set for Breakneck 35% CAGR Growth by 2034 | DelveInsight
The KRAS inhibitors market is projected to witness strong expansion, fueled by the growing burden of cancer, wider access to advanced therapies, and a promising pipeline featuring candidates such as Olomorasib (Eli Lilly), MK-1084 (Merck/Taiho/Astex Pharmaceuticals), Divarasib (Roche), Daraxonrasib (Revolution Medicines), Onvansertib
